Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia

Chronic Myeloid Leukaemia Clinical Trial

Official title:
Randomised Multicentre Phase IV Study to Compare Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec® in Combination With Interferon Alpha at Low Doses in the Treatment of Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukaemia

Status Completed

Clinical Trial Summary

To compare the complete cytogenetic response rate in patients with newly-diagnosed chronic-phase chronic myeloid leukaemia treated with Glivec® alone or in combination with interferon at low doses

Clinical Trial Description

Open, prospective, multicentre, phase IV, comparative and randomised study ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Chronic Myeloid Leukaemia
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Leukemia, Myeloid, Chronic-Phase

Clinical Trial Details

NCT number	NCT00390897
Study type	Interventional
Source	PETHEMA Foundation
Contact
Status	Completed
Phase	Phase 4
Start date	July 2003
Completion date	December 2007

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01475110` - Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib
Recruiting	`NCT05682924` - Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib
Completed	`NCT05286528` - Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
Active, not recruiting	`NCT01597219` - Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers	Phase 2
Active, not recruiting	`NCT01699217` - Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase
Completed	`NCT02546375` - A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands
Active, not recruiting	`NCT01804985` - De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia	Phase 2
Completed	`NCT01343173` - Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib	N/A
Completed	`NCT05893836` - Real-World Disease Management and Outcomes in Chronic Myeloid Leukaemia
Recruiting	`NCT02001818` - Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia	Phase 2
Completed	`NCT01621724` - WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study	Phase 1/Phase 2